Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
BioGeometry logo — Where Protein Design Meets Generative AI and Geometric Deep...

BioGeometry

Where Protein Design Meets Generative AI and Geometric Deep Learning.

Founded 2022 China Beijing, China 12 employees Series A Total: $200.00M Biotechnology

General Information

Company Name BioGeometry
Founded Year 2022
Location China Beijing, China
Employees 12
Industries Biotechnology
Funding Stage Series A
Business Model B2B, SaaS, Platform
Revenue Model Subscription, Usage Based, Project Based
Social

BounceWatch is an independent company data service, not affiliated with BioGeometry. To contact BioGeometry, visit biogeom.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does BioGeometry compare?

A PDF of BioGeometry and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting BioGeometry soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About BioGeometry

BioGeometry, founded in 2022, is an innovative player in the Biotechnology industry. Its slogan, "Where Protein Design Meets Generative AI and Geometric Deep Learning," encapsulates its cutting-edge approach to developing programmable protein medicines.

The company uniquely tackles the longstanding issues of high costs, lengthy development cycles, and low success rates in traditional macromolecular therapeutics. By integrating geometric deep learning, structural biology, immunology, and synthetic biology, BioGeometry leverages a blend of AI capabilities and biological insights.

The team comprises talents from prestigious pharmaceutical firms and top-tier AI and bio labs globally, indicating a robust foundation in both scientific and technological expertise.

Notably, on 01 June 2026, they secured a substantial CNY200.00M Series A investment from prominent backers Gaorong Capital, Anxin Capital, and Fortune Venture. This significant funding underscores investor confidence in their pioneering approach and growth potential.

Business keywords: Protein Design, Generative AI, Geometric Deep Learning, Programmable Medicines, Biotech Innovations, Structural Biology, Immunology, Synthetic Biology, Macromolecular Therapeutics, AI-driven Biotech, Biopharmaceutical R&D, Next-gen Therapies, Therapeutic Optimization, Technology-driven Drug Development, Biological Data Analysis

Services & Products

Generative AI solutions for protein design
Development of next-generation biologics
Bio-manufacturing solutions
Enzyme optimization technologies
Epitope-specific antibody generation

Target Customers

Biopharmaceutical companies Synthetic biology companies Research institutions focusing on drug development Organizations working on sustainable solutions

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series A CNY200.00M 3
Gaorong Capital Anxin Capital
Gaorong Capital, Anxin Capital +1
01 Jun 2026
Seed Undisclosed 4
Gaorong Capital ShengJing360
Gaorong Capital, ShengJing360 +2
01 Jun 2024
Seed Undisclosed 1
Gaorong Capital
Gaorong Capital
01 Sep 2022
Spinout Undisclosed 2
Montréal
Montréal, Montreal Institute for Learning Algorithms
01 Jan 2022

BioGeometry Alternatives & Competitors

View All Alternatives
BioGeometry vs
Tentarix Biotherapeutics
Tentarix Biotherapeutics United States

Enabling Intelligent Therapies with Multifunctional Biologics

Series B
56 employees
Biotechnology, Life Sciences
BioGeometry vs
Generate:Biomedicines
Generate:Biomedicines United States

Pioneering generative biology to create breakthrough therapeutics.

IPO
335 employees
Biotechnology, Pharmaceutical
BioGeometry vs
Profluent
Profluent United States

Grounded in nature, authored by AI

Venture round
83 employees
AI, Biotechnology
View all alternatives

FAQ About BioGeometry

Where Protein Design Meets Generative AI and Geometric Deep Learning.
BioGeometry was founded in 2022.
BioGeometry is headquartered in Beijing, China.
BioGeometry operates in Biotechnology. Its work centres on Protein Design, Generative AI, Geometric Deep Learning and Programmable Medicines. Its customers include Biopharmaceutical companies, Synthetic biology companies and Research institutions focusing on drug development.
BioGeometry has a B2B, SaaS and Platform business model. Its revenue comes from Subscription, Usage Based and Project Based.
BioGeometry has approximately 12 employees.
BioGeometry has completed 4 funding rounds, raising a total of $200.00M. The latest funding stage is Series A.
BioGeometry offers: Generative AI solutions for protein design, Development of next-generation biologics, Bio-manufacturing solutions, Enzyme optimization technologies, Epitope-specific antibody generation.
Top alternatives and competitors to BioGeometry include Tentarix Biotherapeutics, Generate:Biomedicines, Profluent, Adaptyv, Diffuse Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BioGeometry and Tentarix Biotherapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BioGeometry, https://bouncewatch.com/company/biogeometry, updated 6 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout